Drug Trial Radar · NCT06329401
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
398
Actual
Start
Apr 3, 2024
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Avalyn Pharma Inc.Industry
- Sponsor type
- Industry
- Collaborators
- DevPro Biopharma
- First posted
- Mar 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
Conditions
- Pulmonary Fibrosis
- Progressive Pulmonary Fibrosis
- Pulmonary Fibrosis Secondary to Systemic Sclerosis
- Pulmonary Fibrosis, Interstitial Lung Disease
- Interstitial Lung Disease
- Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)
- Interstitial Lung Disease in Patients With Rheumatoid Arthritis
- Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere
- Hypersensitivity Pneumonitis
- Interstitial Lung Disease With Systemic Sclerosis
Interventions
AP01Drug
Oral inhalation solution
PlaceboOther
Placebo oral inhalation solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the effect of AP01 high dose twice a day (BID) or AP01 low dose twice a day (BID) compared to placebo twice a day (BID)Time frame: Week 52
Locations
154 sites in 14 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Mayo Clinic- Scottsdale
Scottsdale, Arizona
University of Southern California
Los Angeles, California
Cedars-Sinai
Los Angeles, California
UCLA
Los Angeles, California
Newport Native MD, Inc.
Newport Beach, California
Paradigm Clinical Research - Redding
Redding, California
University of California - San Francisco
San Francisco, California
University of Colorado, Anschutz Medical Campus
Aurora, Colorado
National Jewish Health
Denver, Colorado
UCONN Health
Farmington, Connecticut
Yale University
New Haven, Connecticut
Clinical Site Partners, LCC
Leesburg, Florida
Renstar Medical Research
Ocala, Florida
Clinical Site Partners
Winter Park, Florida
Piedmont Healthcare, Inc.
Atlanta, Georgia
Northwestern University
Chicago, Illinois
Endeavor Health
Evanston, Illinois
Loyola University Medical Center
Maywood, Illinois
The University of Kansas Medical Center
Kansas City, Kansas
University of Maryland
Baltimore, Maryland
Johns Hopkins University
Baltimore, Maryland
Beth Israel Deaconess Medical Center
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
University of Minnesota
Minneapolis, Minnesota
Mayo Clinic Rochester
Rochester, Minnesota
Hannibal Regional Healthcare System
Hannibal, Missouri
Northern Westchester Hospital
Mount Kisco, New York
Northwell Health - Mount Kisco
Mount Kisco, New York
NYU Langone Health
New York, New York
Weill Cornell
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Columbia University
New York, New York
Montefiore Medical Center
The Bronx, New York
Duke University
Durham, North Carolina
Piedmont HealthCare, PA
Statesville, North Carolina
Accellacare
Wilmington, North Carolina
Southeastern Research Center
Winston-Salem, North Carolina
University of Cincinnati
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Showing 40 of 154 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.